Guggenheim lowered the firm’s price target on Tango Therapeutics (TNGX) to $8 from $18 and keeps a Buy rating on the shares after the company reported quarterly results and provided a clinical update on its PRMT5 inhibitors, TNG908 and TNG462. The update “clearly fell short of investor expectations,” but the firm keeps a Buy rating on shares as the focus shifts to disclosure of more mature data in 2025, adding that it thinks the risk/reward is “more favorable” given the selloff in shares.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNGX:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue